Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AGIO 
Agios Pharm (AGIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: AGIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.36% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.63B USD | Price to earnings Ratio 2.44 | 1Y Target Price 54.57 |
Price to earnings Ratio 2.44 | 1Y Target Price 54.57 | ||
Volume (30-day avg) 756768 | Beta 0.9 | 52 Weeks Range 26.66 - 62.58 | Updated Date 04/2/2025 |
52 Weeks Range 26.66 - 62.58 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1845.92% | Operating Margin (TTM) -1165.3% |
Management Effectiveness
Return on Assets (TTM) -20.47% | Return on Equity (TTM) 57.29% |
Valuation
Trailing PE 2.44 | Forward PE 2.47 | Enterprise Value 733192975 | Price to Sales(TTM) 44.65 |
Enterprise Value 733192975 | Price to Sales(TTM) 44.65 | ||
Enterprise Value to Revenue 20.09 | Enterprise Value to EBITDA -2.33 | Shares Outstanding 57296200 | Shares Floating 50716848 |
Shares Outstanding 57296200 | Shares Floating 50716848 | ||
Percent Insiders 1.52 | Percent Institutions 108.53 |
Analyst Ratings
Rating 4 | Target Price 57 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Agios Pharm
Company Overview
History and Background
Agios Pharmaceuticals was founded in 2008. It initially focused on cancer metabolism and has since expanded to rare genetic diseases. It has evolved from a research-focused company to one with commercial products.
Core Business Areas
- Rare Genetic Diseases: Focuses on developing and commercializing therapies for rare genetic diseases, primarily those related to red blood cells.
Leadership and Structure
The company has a CEO, a CFO, and other key executives. The organizational structure includes research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- PYRUKYND (mitapivat): PYRUKYND is a first-in-class oral PK activator indicated for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Agios currently holds all market share. Competitors: There are no direct competitors currently; however, gene therapies could be an alternative long term.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Focus has increased on rare diseases.
Positioning
Agios positions itself as a leader in rare genetic disease therapeutics, particularly in red blood cell disorders. Its competitive advantage lies in its novel PK activator technology.
Total Addressable Market (TAM)
The TAM for PK deficiency and other red blood cell disorders is estimated to be several billion dollars. Agios is well-positioned to capture a significant portion of this market with PYRUKYND.
Upturn SWOT Analysis
Strengths
- First-in-class therapy
- Strong intellectual property
- Experienced management team
- Focus on rare diseases with unmet needs
Weaknesses
- Reliance on a limited number of products
- High R&D costs
- Market penetration may take time
Opportunities
- Expanding indications for PYRUKYND
- Developing new therapies for other rare genetic diseases
- Geographic expansion
- Partnerships and acquisitions
Threats
- Competition from new therapies
- Regulatory challenges
- Pricing pressure
- Patent expiration
Competitors and Market Share
Key Competitors
- No Direct Competitors
Competitive Landscape
Agios currently has a monopoly, giving them a competitive advantage. This advantage depends on new therapies reaching the market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to the development and commercialization of PYRUKYND. Sales growth will drive the overall trend.
Future Projections: Future projections depend on PYRUKYND market penetration, potential label expansions, and pipeline progress. Analyst estimates available from financial news sources.
Recent Initiatives: Recent initiatives include expanding the PYRUKYND label and advancing pipeline programs.
Summary
Agios Pharmaceuticals is focused on rare genetic diseases and has successfully launched PYRUKYND for PK deficiency. The company faces risks from new therapies entering the market and pricing pressure, but also has opportunities to expand its label and pipeline. It needs to continue to innovate and expand its market reach. Agios' strength is its current monopolistic hold, but that may not last forever.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agios Pharm
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2013-07-24 | CEO & Director Mr. Brian M. Goff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 486 | Website https://www.agios.com |
Full time employees 486 | Website https://www.agios.com | ||
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.